|
|
|
|
|
|
|
International Myositis Society - Newsletter 4/22
|
|
|
|
Upcoming papers on Myositis in press at our home journal "Clinical and Experimental Rheumatology - CER"
|
- In-patient comorbidities in inclusion body myositis: a national in-patient sample-based study
A.K. Ma, F. Dai, B- Roy
- Increased serum levels of sCD40L were associated with rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies
W. Lyu, W. Zhou, Q. Xu, X. Liu, Y. Zhang, Y. Qiu, M. Huang, M. Cao, Y. Xiao, H. Cai, J. Dai
- Anti-TIF1-gamma antibody-positive dermatomyositis caused by camrelizumab in a patient with oesopahgeal cancer
J. Li, S. Yi, Y. Huang, Y. Peng, Z. Yang
These myositis-related articles will appear at CER, and can be found there in the press section.
|
|
|
|
SAVE THE DATE - GENERAL ASSEMBY
|
|
The next iMyoS general assembly will be held virtually on November 22nd, 2022 at 1pm CET (UTC+1). Agenda topics can be sent to info@imyos.org by the end of October.
|
|
Please note that only iMyoS members can attend. You can sign up for membership through the website www.imyos.org
|
|
We look forward to see you in the general assembly.
|
|
|
|
Call for proposals
|
The GCOM conference, considered the premier conference for myositis, is held every two years. Following this year's meeting in Prague and the upcoming meeting in Pittsburgh in 2024, we are calling for proposals to host the sixth GCOM meeting in 2026. The deadline for submission is 07 November 2022.We look forward to receiving your proposal!
|
|
|
|
|
|
|
|
|
|
|
|
